IMPROVED PREDICTIVE VALUE FOR SUSTAINED IMMUNE CONTROL IN PEGINTERFERON ALFA-2A (40KD) (PEGASYS)-TREATED HBEAG-POSITIVE PATIENTS USING COMBINED HBSAG AND HBV DNA LEVELS AT WEEK 24

被引：2
|
作者：
Piratvisuth, T. [1 ]
Chan, H. L. Y. [2 ]
Marcellin, P. [3 ,4 ]
Wat, C. [5 ]
Regep, L. [6 ]
Messinger, D. [7 ]
Kapprell, H. -P. [8 ]
Lu, Z. M. [9 ]
Luo, K. X. [10 ]
机构：
[1] Prince Songkla Univ, Songklanagarind Hosp, NKC Inst Gastroenterol & Hepatol, Dept Internal Med, Hat Yai, Thailand
[2] Chinese Univ Hong Kong, Dept Med & Therapeut, Hong Kong, Hong Kong, Peoples R China
[3] Univ Paris Diderot, Serv Hepatol, Clichy, France
[4] Univ Paris Diderot, INSERM CRB3 U773, Clichy, France
[5] Roche Prod Ltd, Welwyn Garden City AL7 3AY, Herts, England
[6] F Hoffmann La Roche, Basel, Switzerland
[7] IST GmbH, Mannheim, Germany
[8] Abbott GmbH & Co KG, Wiesbaden, Germany
[9] Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, Dept Infect Dis, Shanghai, Peoples R China
[10] So Med Univ, Nanfang Hosp, Dept Infect Dis, Guangzhou, Guangdong, Peoples R China
来源：
JOURNAL OF HEPATOLOGY | 2012年 / 56卷
关键词：
D O I：
10.1016/S0168-8278(12)60551-0
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
538
引用
收藏
页码：S213 / S214
页数：2
相关论文
共 50 条
  • [21] ON-TREATMENT HBSAG DECLINE DURING PEGINTERFERON ALFA-2A (40KD) ± LAMIVUDINE IN PATIENTS WITH HBEAG-POSITIVE CHB AS A POTENTIAL PREDICTOR OF DURABLE OFF-TREATMENT RESPONSE
    Lau, George K.
    Marcellin, Patrick
    Brunetto, Maurizia
    Piratvisuth, Teerha
    Kapprell, Hans-Peter
    Button, Peter
    Batrla, Richard
    HEPATOLOGY, 2008, 48 (04) : 714A - 714A
  • [22] Evidence for the efficacy of peginterferon alfa-2a (40 KD) (pegasys) in the treatment of HBeAg-positive chronic hepatitis B (CHB) and impact of baseline factors
    Cooksley, WGE
    Piratvisuth, T
    Wang, YJ
    Mahachai, V
    Chao, YC
    Tanwandee, T
    Chutaputti, A
    Chang, WY
    Zahm, FE
    Pluck, N
    JOURNAL OF HEPATOLOGY, 2002, 36 : 8 - 8
  • [23] Efficacy and safety of 22 weeks of maintenance therapy with Peginterferon alfa-2a (40KD) (PEGASYS™) alone versus Peginterferon alfa-2a (40KD) plus ribavirin(COPEGUS™) in naive patients with chronic hepatitis C and genotype 1 who responded to a 24-week course of Peginterferon alfa-2a (40KD) plus ribavirin:: An open, multicenter, randomized trial.
    Bronowicki, JP
    Ouzan, D
    Tzanck, A
    Asselah, T
    Desmorat, H
    Zarski, JP
    Foucher, J
    Bourliere, M
    Renou, C
    Tran, A
    Melin, P
    Hezode, C
    Chevallier, M
    Bouvier, M
    Lonjon-Domanec, I
    Pawlotsky, JM
    HEPATOLOGY, 2003, 38 (04) : 244A - 245A
  • [24] TREATMENT OF HBEAG-POSITIVE CHB INFECTION WITH PEGINTERFERON ALFA-2A [40KD] PLUS LAMIVUDINE OR ADEFOVIR FOR 96 WEEKS RESULTS IN HIGH RATES OF HBSAG CLEARANCE/SEROCONVERSION
    Cao, Zhenhuan
    Zhang, Yonghong
    Ma, Lina
    Jin, Yi
    Yu, Haibin
    Zhang, Xiao-dan
    Liu, Yali
    Huang, Yanxiang
    Ma, Bing
    Ren, Shan
    Wang, Lilin
    Chen, Xin-Yue
    Wei, Lai
    HEPATOLOGY, 2010, 52 (04) : 507A - 507A
  • [25] HIGH LEVELS OF HBSAG AND HBV DNA DURING TREATMENT PREDICT FAILURE FOR HBEAG SEROCONVERSION IN HBEAG POSITIVE CHRONIC HEPATITIS B PATIENTS TREATED WITH PEGINTERFERON ALFA-2A (PEGASYS®) AND ADEFOVIR (HEPSERA); AN INTERIM ANALYSIS
    Takkenberg, Bart
    Zaaijer, Hans L.
    de Niet, Annikki
    Weegink, Christine J.
    Terpstra, Valeska
    Koot, Maarten
    Dijkgraaf, Marcel
    Jansen, Peter L.
    Janssen, Harry L.
    Beld, Marcel
    Reesink, Hendrik W.
    HEPATOLOGY, 2009, 50 (04) : 541A - 541A
  • [26] Effect of ethnicity, genotype, gender, age and bodyweight on sustained response in a large, randomised study of peginterferon alfa-2A (40KD) (PEGASYS®) +/- lamivudine versus lamivudine alone for HBEAG-positive chronic hepatitis B
    Chow, WC
    Manns, M
    Paik, SW
    Berg, T
    Piratvisuth, T
    Chang, WY
    Lau, GK
    Marcellin, P
    Gane, E
    Pluck, N
    HEPATOLOGY, 2005, 42 (04) : 576A - 576A
  • [27] BASELINE HBSAG LEVELS PREDICT HBSAG LOSS IN HBEAG NEGATIVE BUT NOT IN HBEAG POSITIVE CHRONIC HEPATITIS B PATIENTS TREATED WITH PEGINTERFERON ALFA-2A (PEGASYS®) AND ADEFOVIR (HEPSERA): AN INTERIM ANALYSIS
    Takkenberg, Bart
    Zaaijer, Hans L.
    de Niet, Annikki
    Weegink, Christine J.
    Terpstra, Valeska
    Koot, Maarten
    Dijkgraaf, Marcel
    Jansen, Peter L.
    Janssen, Harry L.
    Beld, Marcel
    Reesink, Hendrik W.
    HEPATOLOGY, 2009, 50 (04) : 536A - 537A
  • [28] Suppression of HBV DNA in patients with HBeAg-negative CHB treated with peginterferon alfa-2A (40KD) ± lamivudine:: 2-year follow-up results
    Marcellin, Patrick
    Bonino, Ferruccio
    Lau, George K.
    Farci, Patrizia
    Yurdaydin, Cihan
    Piratvisuth, Teerha
    Luo, Kangxian
    Gurel, Selim
    Hadziyannis, Stephanos
    Wang, Yuming
    Popescu, Matei
    HEPATOLOGY, 2006, 44 (04) : 550A - 550A
  • [29] EFFICACY AND SAFETY OF PEGINTERFERON alfa-2a (40KD) IN HBeAg-POSITIVE CHRONIC HEPATITIS B PATIENTS PARTICIPATING IN A RESPONSE-GUIDED THERAPY STUDY: AN INTERIM ANALYSIS AT WEEK 72
    Hou, J.
    Ma, H.
    Sun, J.
    Xie, Q.
    Xie, Y.
    Sun, Y.
    Wang, H.
    Shi, G.
    Wan, M.
    Niu, J.
    Ning, Q.
    Yu, Y.
    Zhao, Y.
    JOURNAL OF HEPATOLOGY, 2013, 58 : S303 - S304
  • [30] Prediction of sustained virological response in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD) and ribavirin
    Foster, Graham R.
    Fried, Michael W.
    Hadziyannis, Stephanos J.
    Messinger, Diethelm
    Freivogel, Klaus
    Weiland, Ola
    SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2007, 42 (02) : 247 - 255
12345